Interim SMMUSD co-superintendents introduced

first_imgHomeNewsEducationPublicInterim SMMUSD co-superintendents introduced Jul. 25, 2016 at 6:31 amPublicInterim SMMUSD co-superintendents introducedJeff Goodman5 years agoboard of educationchris kingeducationemploymentjacqueline seabrookslaurie liebermanpedro nogueraPico NeighborhoodRichard Tahvildaran-Jessweinrick colesandra lyonSanta Monicasanta monica californiasanta monica daily presssanta monica high schoolsanta monica newssarah braffschool boardsmmusdsylvia rousseauTerry Deloria At its first meeting in three weeks, the local Board of Education last week conducted business with two new faces on the dais.The school board on July 20 officially welcomed interim co-superintendents Chris King and Sylvia Rousseau to the Santa Monica-Malibu school district, which is currently searching for Sandra Lyon’s long-term replacement as it gears up for the 2016-17 school year.Board president Laurie Lieberman said SMMUSD is “unbelievably fortunate” to have King and Rousseau as temporary leaders through the end of the calendar year.“Our district is really lucky and is going to have a good six months with the two of them at the helm,” Lieberman said. “We can already see it in their ability to work together and take on all of the many things that make our district what it is and keep our district moving in the right direction.”Over the last few weeks, King and Rousseau has been traveling to various school sites, meeting with principals and getting caught up on work in the district. They have also had discussions with board members and district staff.It’s a homecoming of sorts for Rousseau, a longtime schools administrator in the region who served as principal at Santa Monica High School from 1993 to 2000.“I’m happy to be back,” she said. “I’m looking forward to a really productive six months. I plan to enjoy it.”Of particular importance to Rousseau is keeping alive the momentum on Pedro Noguera’s efforts to improve equity in the district. She and King have met with the education reformist.“We’re looking at ways to take his report and turn it into action,” Rousseau said. “That’s where the difficulty is.”Both interim chiefs are likely to attend the district’s annual convocation Aug. 17, when Noguera will deliver a keynote speech. The district hired him as a consultant last year to help SMMUSD close longstanding achievement gaps between minority and low-income students and their peers.“It’s a pleasure knowing we can continue doing the work we’re doing,” said Terry Deloria, the district’s assistant superintendent for educational services.King and Rousseau have also met with Santa Monica police Chief Jacqueline Seabrooks and City Manager Rick Cole, among other local leaders.“I’m trying to be out in the community as much as possible so people can put a name to a face,” King said.King said he’s enjoyed the vibrancy of the Pico Neighborhood, where he has an apartment. But he told board member Richard Tahvildaran-Jesswein, a Santa Monica College professor, that noisy students living near the campus have kept him awake at night.“Richard, you need to assign a little more homework,” King joked.King, who recently served as interim superintendent in the Anaheim City School District, said he “couldn’t be happier” to be working in SMMUSD and thanked the board and district leaders for making him feel comfortable as he settles into his new job.“We hope you continue to feel that way,” Lieberman said.Sarah Braff, who represents the Santa Monica-Malibu Classroom Teachers Association, welcomed the co-superintendents to the district’s “jolly boat” and said she’s anticipating genuine collaboration on equity work, bias training and other issues.“I hope we’ll all be rowing together,” she [email protected] :board of educationchris kingeducationemploymentjacqueline seabrookslaurie liebermanpedro nogueraPico NeighborhoodRichard Tahvildaran-Jessweinrick colesandra lyonSanta Monicasanta monica californiasanta monica daily presssanta monica high schoolsanta monica newssarah braffschool boardsmmusdsylvia rousseauTerry Deloriashare on Facebookshare on Twitteradd a commentBail set at $10,000 for Rite Aid theft suspectBallot measures headed for City Council approvalYou Might Also LikeFeaturedNewsDraft Housing Element released to publicBrennon Dixson2 weeks agoFeaturedNewsRent Board announces general adjustment effective SeptemberBrennon Dixson3 weeks agoFeaturedNewsCommissioners talk diversity, or a lack thereofBrennon Dixson3 weeks agoFeaturedNewsSMMUSD breaks down budget revisionsBrennon Dixson3 weeks agoFeaturedNewsCity Manager selection process beginsBrennon Dixson4 weeks agoFeaturedNewsSmall businesses in Santa Monica amongst hardest hit by Covid in the nationClara Harter1 month agolast_img read more

Von der Leyen hopes for vaccine by ‘autumn,’ defying expert predictions

first_imgEuropean Commission President Ursula von der Leyen said the regulatory process for vaccines could be sped up as she defended a suggestion that a shot against coronavirus could be on the market “before autumn.”That timeline is much faster than what’s foreseen by public health authorities, who expect another year to 18 months for an immunization to be available to the general public.Von der Leyen earlier on Tuesday expressed optimism following talks with CureVac, a biotech company working on a coronavirus vaccine. The EU has offered the company €80 million in financial backing. “I hope that with this support, we can have a vaccine on the market, perhaps before autumn,” she said. Vaccines, like all medicines, need to undergo a series of clinical trials before authorities decide if they can be sold. Von der Leyen, a trained medical doctor, expressed confidence that in this case the normal procedures could be fast-tracked.”As we are in a severe crisis, we all see that we are able to speed up any of the processes that are slow normally and take a lot of time and are very bureaucratic,” she told a later press conference.Even though officials in both the U.S. and Europe have pledged to move as quickly as possible, they’ve consistently cautioned that a vaccine won’t be ready to jab in people’s arms in 2020.“I still believe we will be lucky to get a vaccine for mass use in a year from the start of this,” Patrick Vallance, the U.K.’s chief scientific adviser, told reporters Tuesday. “That would be extraordinary.”Von der Leyen said her autumn aspirations came from CureVac itself. “They are highly specialized in this field, and it’s their prediction that they might be able, towards fall, to have the possibility to have a vaccine that is fighting coronavirus,” she said.In an interview with German media site Sport1 published Monday, CureVac majority investor Dietmar Hopp said timing depends on the German national regulator. However, he added, the shot “ought to be available in autumn” in case the virus comes back after the summer. Von der Leyen pointed to the reports that the U.S. had tried to woo CureVac as evidence “that they [the company] are the frontrunner in the research.”However, with multiple vaccines in development around the globe, CureVac’s isn’t the furthest along. On Monday, a Phase 1 trial began in the U.S. as the first volunteer received an injection of an experimental vaccine by the drugmaker Moderna.A CureVac official told reporters Tuesday that the company aims to start Phase 1 testing by “early summer.”Carmen Paun, Hans von der Burchard and David M. Herszenhorn contributed reporting. Also On POLITICO Coronavirus: Live updates By POLITICO Coronavirus in Europe: Coverage in full By POLITICOcenter_img On Tuesday, Thorsten Schüller, a CureVac spokesman, told POLITICO that going through all three phases of the clinical trials process normally takes “years,” but he declined to respond to von der Leyen’s predicted timeline.Given the clamor for a coronavirus vaccine, he added, “We assume that the process will be shortened. This depends on the authorities.”CureVac is at the center of a German-U.S. dispute, with Berlin accusing U.S. President Donald Trump of trying to poach the company and have its vaccines produced exclusively for the U.S. American officials have rejected reports about Trump’s grab for vaccine exclusivity as “wildly overplayed.” The company echoed that denial on Tuesday.Trump has been frequently contradicted by his government’s public health experts after expressing hope that a coronavirus vaccine would be ready within months. The director of the U.S. National Institute of Allergy and Infectious Diseases said a vaccine won’t be ready for “a year to a year and a half,” even though “this is the fastest we have ever gone from a sequence of a virus to a trial.”Likewise, the European Medicines Agency is ready to evaluate vaccines “within the shortest possible timelines,” the EU drug regulator’s deputy executive director, Noël Wathion, told health ministers on March 6. Early trials won’t start before April or May, Wathion said.Phase 1 trials study whether the vaccine is safe and has any impact in a small number of people. Subsequent phases of trials would study the shot in more people to see whether it really works; what the right dosage is; and what longer-term effects it has. Potential coronavirus vaccines won’t be ready for large-scale clinical studies until “several months from now,” Wathion said.last_img read more